| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : EBb 761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 39.2+/-14.0 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 500 mg (single dose)Result : NegativeRemark : Subject treatment: Normal glucose tolerance (NGT) subjects Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : EBb 761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 39.2+/-14.0 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 500 mg (single dose)Result : NegativeRemark : Subject treatment: Normal glucose tolerance (NGT) subjects Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : EBb 761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 39.2+/-14.0 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 500 mg (single dose)Result : NegativeRemark : Subject treatment: Normal glucose tolerance (NGT) subjects Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : EBb 761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 39.2+/-14.0 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 500 mg (single dose)Result : NegativeRemark : Subject treatment: Normal glucose tolerance (NGT) subjects Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : EGb 761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 51.7+/-8.9 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 250-850 mgResult : NegativeRemark : Subject treatment: Type 2 diabetes mellitus (T2DM) patients T2DM subject took his/her prescribed metformin dose (250-850 mg) with 120 mg EGb 761 Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : EGb 761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 51.7+/-8.9 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 250-850 mgResult : NegativeRemark : Subject treatment: Type 2 diabetes mellitus (T2DM) patients T2DM subject took his/her prescribed metformin dose (250-850 mg) with 120 mg EGb 761 Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : EGb 761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 51.7+/-8.9 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 250-850 mgResult : NegativeRemark : Subject treatment: Type 2 diabetes mellitus (T2DM) patients T2DM subject took his/her prescribed metformin dose (250-850 mg) with 120 mg EGb 761 Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : EGb 761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 20 (M/F=8/12)N(Treatment) : 10 (M/F=4/6)Sex : Both sexAge : 51.7+/-8.9 yearsRoute : Oral administrationDose/Conc.(herb) : 120 mg/day as a single doseDuration : 3 monthsType of interaction : PharmacokineticsInteraction with drug : MetforminDose/Conc.(drug) : 250-850 mgResult : NegativeRemark : Subject treatment: Type 2 diabetes mellitus (T2DM) patients T2DM subject took his/her prescribed metformin dose (250-850 mg) with 120 mg EGb 761 Results: The pharmacokinetic parameters of metformin were all significantly different (P<0.05) between the NGT (500 mg) and 8 out of 10 of the T2DM subjects who were prescribed 500 mg of metformin during the placebo cycles. During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05). Conclusion: The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of metformin.
